Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus-related cirrhosis.

about

Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus-related cirrhosis.

Item

http://www.wikidata.org/entity/Q55069588

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Sofosbuvir induced steven John ...... tis C virus-related cirrhosis.

@en

Sofosbuvir induced steven John ...... tis C virus-related cirrhosis.

@nl

type

Item

label

Sofosbuvir induced steven John ...... tis C virus-related cirrhosis.

@en

Sofosbuvir induced steven John ...... tis C virus-related cirrhosis.

@nl

prefLabel

Sofosbuvir induced steven John ...... tis C virus-related cirrhosis.

@en

Sofosbuvir induced steven John ...... tis C virus-related cirrhosis.

@nl

P1476

Sofosbuvir induced steven John ...... tis C virus-related cirrhosis.

@en

P2093

Gitesh Sawatkar

http://www.w3.org/2001/XMLSchema#string

Shreya Singh

http://www.w3.org/2001/XMLSchema#string

Virendra Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting.

ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Stevens-Johnson syndrome: pathogenesis, diagnosis, and management.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.

Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.

Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis.

Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.

Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.

P304

16-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP4.1126

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nipun Verma

P577

2017-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29404508

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir

P932

5776873

http://www.w3.org/2001/XMLSchema#string